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Abstract	In	 production	 of	 recombinant	 proteins	 for	 biopharmaceuticals,	 N-glycosylation	 is	 often	important	for	protein	efficacy	and	patient	safety.	IgG	with	agalactosylated	(G0)-N-glycans	can	improve	the	activation	of	the	complement	system	and	be	advantageous	in	the	therapy	of	 lupus	 and	 virus	 diseases.	 In	 this	 study,	 we	 aimed	 to	 engineer	 CHO-S	 cells	 for	 the	production	 of	 proteins	 with	 G0-N-glycans	 by	 targeting	 B4Gal-T	 isoform	 genes	 with	CRISPR/Cas9.	 Indel	 mutations	 in	 genes	 encoding	 B4Gal-T1,	 -T2,	 –T3	 with	 and	 without	disrupted	 B4Gal–T4	 sequence	 resulted	 in	 only	 ~1%	 galactosylated	 N-glycans	 on	 total	secreted	protein	of	three	clones	per	genotype.	In	the	triple-KO	clones,	transiently	expressed	erythropoietin	(EPO)	and	transiently	expressed	rituximab	harbored	only	~6%	and	~3%	galactosylated	N-glycans,	respectively.	However,	simultaneous	disruption	of	B4Gal-T1,	-T2	and	–T3	was	 found	 to	decrease	 cell	 growth.	We	 furthermore	 revealed	possible	B4Gal-T	isoform	branch	preferences	where	B4Gal-T2	activity	is	restricted	to	act	on	a	single	N-glycan	branch	and	B4Gal-T4	was	found	to	be	inactive	in	N-glycan	galactosylation	in	CHO-S	cells.	Altogether,	we	present	 the	advantage	of	analyzing	total	secreted	protein	N-glycans	after	disrupting	glycosyltransferases	 followed	by	expressing	recombinant	proteins	 in	selected	clones	 with	 desired	 N-glycan	 profiles	 at	 a	 later	 stage.	 Furthermore,	 we	 provide	 a	 cell	platform	 that	 prevalently	 glycosylates	 proteins	 with	 G0-N-glycans	 to	 further	 study	 the	impact	 of	 agalactosylation	 on	 different	 in	 vitro	 and	 in	 vivo	 functions	 of	 recombinant	proteins.	
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1.	Introduction	Chinese	hamster	ovary	(CHO)-derived	cells	are	the	major	workhorses	within	mammalian	cell	 lines	 and	 represent	 the	 cell	 platform	 in	which	 >50%	 of	 the	marketed	 recombinant	proteins	 are	 produced[1].	 Thereof,	 recombinant	monoclonal	 antibodies	 (mAbs)	 are	 the	main	 product	 subclass	 and	 are	 utilized	 for	 the	 treatment	 of	 cancer	 and	 various	inflammatory	diseases[2].	As	a	result	of	post-translational	protein	processing,	mAbs	harbor	two	N-glycans,	one	on	each	heavy	chain	at	Asparagine	(Asn)	297	whereas	erythropoietin	(EPO)	has	three	N-glycosylation	sites	occupied	by	predominantly	tri-	and	tetra-antennary	structures	[3].	In	general,	N-glycosylation	can	impact	protein	folding,	immune	regulation,	cellular	homeostasis	and	the	biological	half-life	of	proteins[4,	5].	Within	mAbs,	the	fragment	crystallizable	 (Fc)	 N-glycans	 at	 Asn297	 have	 a	 strong	 influence	 on	 anti-inflammatory	properties,	 antibody-dependent	 cell-mediated	 cytotoxicity	 and	 complement-dependent	cytotoxicity[6].	The	heterogeneous	N-glycan	profile	of	glycoproteins	produced	in	CHO	is	one	of	the	main	factors	 that	 cause	 mAb	 heterogeneity	 and	 can	 be	 further	 optimized	 regarding	 core-fucosylation,	galactosylation,	antennarity	and	terminal	capping	by	sialic	acids.	Rituximab	is	an	 immunoglobulin	 G	 (IgG)	 1-class	 molecule,	 one	 of	 the	 recombinant	 glycoproteins	produced	in	CHO,	and	exceeds	annual	revenues	of	USD	7	billion[7].	Rituximab	targets	the	B-cell	 surface	antigen	CD20	 in	B-cell	 lymphoma	and	 is	predominantly	N-glycosylated	by	A2FG0	and	A2FG1	structures	when	produced	in	non-glyco-engineered	CHO	cells[8].	Since	several	studies	revealed	non-fucosylated	IgGs	have	significantly	higher	binding	affinity	for	the	 Fc-gamma	 receptor	 IIIa	 (FcγRIIIa)	 than	 fucosylated	 IgG	 versions[9,	 10],	 different	approaches	 successfully	 removed	 the	 core-fucose	 by	 knockout	 of	 alpha-(1,6)-fucosyltransferase	(FUT8)	or	tissue	specific	transplantation	antigen	P35B	(TSTA3)	in	IgG-expressing	CHO	cell	lines[11–14].	
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Additionally,	 agalactosylated	 IgG1	 variants	with	 terminal	N-Acetylglucosamine	 (GlcNAc)	(referred	to	as	G0	glycoforms)	can	increase	the	binding	to	FcRIIIa[15]	and	are	accessible	for	the	mannose-binding	protein.	They	can	 therefore	promote	activation	of	the	complement	system[16]	without	 impacting	 in	 vivo	 clearance[17–19].	 Furthermore,	HIV	patients	with	high	 viral	 inhibition	 displayed	 an	 increased	 proportion	 of	 agalactosylated	 N-glycans	 on	global	 serum	 IgG,	 suggesting	 that	 agalactosylated	 IgG	 variants	 may	 have	 antiviral	activity[20].	 Interestingly,	 Lupus	 patients	 showed	 improved	 disease	 symptoms	 after	treatment	with	agalactosylated	antibodies[21].	These	G0-IgG	variants	can	be	obtained	by	sequential	 treatment	 of	 wild	 type	 (WT)-IgG	 with	 neuraminidase	 and	 galactosidase	 or	supplementing	cultivation	medium	with	galactose	analogues	to	block	cellular	B4Gal-Ts[22].	Nevertheless,	fewer	cell-engineering	attempts	were	initiated	to	produce	G0-IgG1	compared	to	engineering	non-fucosylated	IgG1	variants.	Since	 the	 CHO	 genome	 sequence	 is	 publically	 available[23],	 CHO	 cell-engineering	 is	 no	longer	performed	in	a	“black	box”,	which	shortens	cell	line	development	and	empowers	a	targeted	 approach	 for	 the	 engineering	 of	 a	 G0	 CHO	 cell	 line.	 The	 classes	 of	glycosyltransferases	 are	 made	 of	 homologous	 gene	 families,	 where	 the	 class	 of	 β-1,4-galactosyltransferases	 (B4GalT)	 consists	 of	 seven	 members,	 B4Gal-T1–T7,	 which	 all	transfer	 galactose	 from	uridine	diphosphate	 galactose	 (UDP-Gal)	 to	GlcNAc	and	GlcNAc-terminated	 oligosaccharides	 (EC	 2.4.1.38)[24,	 25].	 The	 seven	 CHO	 B4Gal-Ts	 all	 share	 a	common	 WGXEDD	 sequence	 as	 part	 of	 their	 B4Gal-T	 motif[26]	 and	 have	 exclusive	specificity	 for	 the	 donor	 substrate	 UDP-Gal.	 B4Gal-T5	 and	 -T6	 are	 described	 to	mainly	function	 in	 O-glycosylation[27,	 28],	 whereas	 B4Gal–T7	 transfers	 UDP-Gal	 within	glycosaminoglycan	 biosynthesis	 and	 therefore	 is	 not	 involved	 in	 the	 N-glycosylation	 of	proteins[29,	 30].	 A	 further	 study	 indicated	 that	 B4Gal-T1,	 -T2,	 -T3	 and	 –T4	 perform	N-glycan	galactosylation	more	efficient	than	B4Gal-T5	and	-T6	and	suggested	different	branch	preferences	for	the	family	members	of	β-1,4-galactosyltransferases[31].	In	addition,	B4Gal-
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T4	is	reported	to	also	be	active	in	the	galactosylation	of	mucin-type	core	2	branching	in	the	O-glycosylation	 pathway[32].	 Another	 study	 described	 B4Gal-T1-KO	 mutants	 to	 have	dramatically	reduced	galactosylation	on	secreted	host	cell	protein	(secretome)	N-glycans	and	reduced	growth	of	mice[28,	33].	In	a	previous	study	performed	with	CHO-K1	derived	cell	lines,	triple-KO	of	B4Gal-T1,	-T2	and	–T3,	double-KO	of	B4Gal-T1	and	-T3	and	single-KO	of	B4Gal-T1	led	to	almost	fully	agalactosylated	EPO	and	rituximab[34].	However,	that	study	was	based	on	only	one	 clone	per	KO-combination	and	 therefore	did	not	 consider	 clonal	variation	and	did	not	investigate	the	impact	of	B4Gal-T	disruptions	on	cell	growth.	Although	this	suggests	B4Gal-T1	and	–T3	to	be	the	main	players	in	galactosylation	of	rituximab	and	EPO	N-glycans	in	CHO-K1	cells,	the	N-glycosylation	activity	of	B4Gal-T1,	-T2,	-T3	and	–T4,	specifically	 in	 the	 industrially	 relevant	 CHO-S	 cell	 line,	 needs	 to	 be	 further	 explored	 to	generate	a	fully	G0	cell	line	within	CHO-S	cells.	Since	the	effect	of	single	disruptions	of	B4Gal-T1,	-T2,	-T3	and	-T4	on	N-glycosylation	was	investigated	in	previous	work[34],	we	designed	a	multiplexing	approach	to	disrupt	combinations	of	up	to	four	B4Gal-Ts.	The	target	design	for	the	multiplexing	approach	contained	B4Gal-T1,	B4Gal-T3	or	both	targets	in	combination	with	B4Gal-T2	and/or	B4Gal-T4.	With	the	help	of	multiplexing,	the	effect	of	stacking	B4Gal-T	disruptions	could	be	studied	with	regards	to	cell	growth	and	protein	N-glycosylation	on	three	clones	for	each	triple-	and	quadruple-KO	combination	to	additionally	examine	clonal	variation.	In	this	work,	we	used	clustered	regularly	interspaced	short	palindromic	repeats/CRISPR-associated	protein	9	(CRISPR/Cas9)	as	a	tool	for	multiplexed	editing	of	gene	targets	within	the	same	transfection[13].	B4Gal-T1	and	–T3	as	well	as	B4Gal–T2	and	–T4	were	disrupted	simultaneously	to	facilitate	investigation	of	the	combinatorial	effect	of	B4Gal-T	knockouts	on	N-glycosylation	and	cell	growth.	N-glycosylation	analysis	of	total	secreted	proteins,	as	well	 as	 transiently	 expressed	 rituximab	 and	 EPO	 (representing	 dissimilar	 N-glycan	profiles),	in	B4Gal-T	edited	CHO-S	cell	lines	was	performed.	The	analysis	demonstrates	that	
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N-glycans	can	be	tailored	for	a	greater	variety	of	secreted	glycoproteins,	as	represented	by	more	than	250	proteins	within	the	CHO-S	secretome[35]	in	addition	to	EPO	and	rituximab.	With	this,	we	investigated	if	screening	the	secretome	N-glycans	of	our	engineered	clones	is	a	promising	strategy	towards	the	expression	of	rituximab	and	EPO	with	G0	N-glycans	in	selected	clones.	The	strategy	was	built	on	(i)	analyzing	the	N-glycan	profile	of	all	secreted	proteins	 from	 selected	multiplexed	 clones	 to	 then	 (ii)	 expressing	 rituximab	and	 EPO	 in	selected	clones	for	rituximab/EPO	N-glycan	analysis	and	(iii)	evaluating	of	the	role	of	each	targeted	B4Gal-T	within	the	galactosylation	of	N-glycans.	Especially	the	role	of	B4Gal-T2	and	–T4	in	CHO-S	and	the	effect	of	B4Gal-T	indels	on	cell	growth,	both	with	respect	to	clonal	variation,	have	 to	our	knowledge	not	been	 investigated	previously	and	were	 the	driving	motives	of	this	work.		
2.	Materials	and	methods	
2.1.	sgRNA	and	GFP_2A_Cas9	plasmid	design	GFP_2A_Cas9	 and	 single	 guide	 RNA	 (sgRNA)	 plasmids	 were	 constructed	 as	 previously	described	[13].	The	sgRNA	target	design	for	B4Gal-T1,	B4Gal-T2,	B4Gal-T3	and	B4Gal-T4	was	performed	using	CRISPy[36].	The	target	sites	for	the	mentioned	genes	and	the	oligos	for	sgRNA	cloning	are	listed	in	Supporting	Information,	Table	S1	and	Table	S2,	respectively.			
2.2.	Cell	cultivation	and	transfection	for	multiplexed	genome	editing	CHO-S	 suspension	 cells	 (Life	 Technologies,	 Carlsbad,	 CA)	 were	 cultivated	 in	 CD	 CHO	medium	 supplemented	 with	 8	mM	 L-glutamine	 and	 1	 μL/mL	 anti-clumping	 agent	 (Life	Technologies).	Cells	were	incubated	in	a	humidified	incubator	at	120	rpm,	37°C	and	5%	CO2.	Cell	passaging	was	conducted	every	two	to	three	days	at	3	x	105	cells/mL	after	measuring	viable	 cell	 densities	 (VCDs)	 and	viabilities	with	 the	NucleoCounter	NC-200	Cell	 Counter	(ChemoMetec,	Allerod,	Denmark).	One	day	prior	transfection	with	CRISPR	reagents,	anti-
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clumping	agent	was	removed	by	centrifugation	and	5	-	6	x	105	cells/mL	were	seeded	in	a	six	multi-well	well	plate	(BD	Biosciences,	San	Jose,	CA)	for	each	transfection.	At	the	day	of	transfection	each	sample	was	seeded	at	1	x	106	cells/mL	and	a	total	DNA	load	of	3.5	μg	was	transfected	with	FuGENE®	HD	transfection	reagent	(Promega,	Madison,	WI)	and	OptiPRO	SFM	medium	(Life	Technologies)	according	to	the	manufacturer´s	recommendations.	The	GFP_2A_Cas9	/	sgRNA	plasmid	ratios	for	each	sample	are	presented	in	Table	S3.	To	measure	transfection	 efficiency,	 pmaxGFP®	 vector	 (Lonza,	 Basel,	 Switzerland)	 transfection	 was	performed.	Cells	were	harvested	for	fluorescence-activated	cell	sorting	(FACS)	48	h	after	transfection.		
2.3.	Single	cell	cloning	using	FACS	Before	FACS,	cells	were	filtered	through	a	40	μm	cell	strainer	into	a	FACS-compatible	tube.		Operating	a	FACSJazz	(BD	Biosciences)	single	 fluorescent-positive	cells	were	sorted	 into	384-well	 plates	 (Corning,	 New	 York,	 NY)	 already	 containing	 30	 μL	 CD	 CHO	 medium	supplemented	with	8	mM	L-glutamine,	1.5%	HEPES	buffer	and	1%	Antibiotic-Antimycotic	(Gibco,	Waltham,	MA)	per	well.	For	cell	sorting,	fluorescent-positive	cell	populations	were	gated	based	on	non-transfected	WT	CHO-S	cells.	Two	weeks	after	cell	 sorting	the	clones	were	 moved	 to	 96-well	 flat-bottom	 plates	 (BD	 Biosciences)	 and	 expanded	 for	 deep	sequencing	analysis	and	batch	cultivation.		
2.4.	Deep	sequencing	analysis	Confluent	colonies	from	96-well	flat-bottom	replicate	plates	were	harvested	for	genomic	DNA	extraction.	DNA	extraction	was	performed	using	QuickExtract	DNA	extraction	solution	(Epicentre,	Illumina,	Madison,	WI)	according	to	the	manufacturer´s	instruction.	The	library	preparation	was	based	on	Illumina	16S	Metagenomic	Sequencing	Library	Preparation	and	deep	sequencing	was	carried	out	on	a	MiSeq	Benchtop	Sequencer	(Illumina,	San	Diego,	CA).	
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The	 protocol	 for	 amplifying	 the	 targeted	 genomic	 sequences,	 amplicon	 purification,	adapter-PCR	and	following	quality	analysis	was	based	on	previously	published	work	[13].	PCR	primers	are	presented	in	Supporting	information,	Table	S4.		
2.5.	Batch	cultivation	to	study	cell	growth	and	secretome	N-glycans	For	batch	cultivation	and	secretome	analysis,	 cells	were	seeded	at	3.0	x	105	cells/mL	 in	Corning	vent	cap	shake	flasks	(Sigma-Aldrich,	St.	Louis,	MI)	as	duplicates	in	30	mL	CD	CHO	medium	 supplemented	 with	 8	mM	 L-glutamine	 and	 1	 μL/mL	 anti-clumping	 agent	 (Life	Technologies).	Cells	were	incubated	in	a	humidified	incubator	at	120	rpm,	37°C	and	5%	CO2.	Cell	densities	and	viabilities	were	determined	once	per	day	using	the	NucleoCounter	NC-250	Cell	Counter	(ChemoMetec).	Secretome	sample	volume	was	calculated	to	harbor	20	x	106	cells	and	harvested	five	days	after	seeding	to	be	pooled	within	biological	replicates.		
	
2.6.	Batch	cultivation	for	transient	rituximab/EPO	transfection	and	rituximab/EPO	
N-glycan	analysis	For	 transient	expression	of	rituximab/EPO,	cells	were	seeded	 in	Corning	vent	cap	shake	flasks	(Sigma-Aldrich)	as	duplicates	with	cell	densities	~1	x	106	cells/mL	in	60	mL	CD	CHO	medium	supplemented	with	8	mM	L-glutamine	(Life	Technologies).	Cells	were	incubated	in	a	humidified	incubator	at	120	rpm,	37°C	and	5%	CO2	and	transfected	with	75	μg	of	rituximab	or	 EPO	 encoding	 plasmid	 for	 each	 flask	 using	 FreeStyleTM	 MAX	 reagent	 together	 with	OptiPRO	 SFM	 medium	 (Life	 Technologies)	 according	 to	 the	 manufacturer´s	recommendations.	 1μL/mL	 anti-clumping	 agent	 was	 added	 24	 h	 after	 transfection.	pmaxGFP®	vector	(Lonza)	transfection	was	performed	to	measure	transfection	efficiencies.	Cell	densities	and	viabilities	were	determined	once	per	day	using	the	NucleoCounter	NC-250	 Cell	 Counter	 (ChemoMetec).	 To	 purify	 rituximab	 and	 EPO,	 the	 supernatants	 of	 the	
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transfected	 clones	 were	 harvested	 three	 days	 after	 transfection	 and	 pooled	 within	duplicates.		
2.7.	Rituximab	and	EPO	purification	For	rituximab	purification,	supernatant	samples	were	centrifuged	(1000	g,	5	minutes,	4°C)	and	afterwards	filtered	(~0.22	μm	pore	size)	to	remove	cells	and	cell	debris.	Rituximab	was	purified	by	protein	A	affinity	chromatography	(MabSelect,	GE	Healthcare,	Uppsala,	Sweden)	according	 to	 the	 manufacturer´s	 protocol.	 Human	 protein	 C4	 (HPC4)-tagged	 EPO	 was	purified	 from	 supernatants	 using	 Anti-Protein	 C	 Affinity	 Matrix	 from	 Roche	 (Basel,	Switzerland,	Cat.	Nr.	11815024001)	as	per	the	instructions	of	the	manufacturer.			
2.8.	N-Glycan	analysis		Sample	preparation	for	N-glycan	analysis	was	performed	with	GlycoWorks	RapiFluor-MS	N-Glycan	 Kit	 (Waters,	 Milford,	 MA)	 according	 to	 the	 manufacturer´s	 instruction.	 12	 μg	purified	 protein	 or	 12	 μl	 of	 10x	 concentrated	 (Amicon	 Ultra-15,	 Merck,	 Darmstadt,	Germany)	secretome	sample	were	used	for	each	sample.	Labeled	N-Glycans	were	analyzed	by	a	LC-MS	system	using	a	Thermo	Ultimate	3000	HPLC	with	fluorescence	detector	coupled	on-line	to	a	Thermo	Velos	Pro	Iontrap	MS,	as	described	previously	with	minor	modifications	[13].	Separation	gradient	30%	to	43%	buffer	and	MS	was	run	in	positive	mode.	Amount	of	N-Glycan	 was	 measured	 by	 integrating	 the	 areas	 under	 the	 normalized	 fluorescence	spectrum	peaks	with	Thermo	Xcalibur	software	(Thermo	Fisher	Scientific,	Waltham,	MA)	giving	the	normalized,	relative	amount	of	the	glycans.	
	
3.	Results		
	
	 10 
3.1.	Generation	of	engineered	CHO-S	cell	lines	with	combinations	of	indels	in	multiple	
B4Gal-T	genes	To	 investigate	 the	 exact	 impact	 of	 B4Gal-T1,	 -T2,	 -T3	 and	 –T4-KO	 on	 N-glycan	galactosylation,	we	aimed	to	generate	clones	with	insertion	or	deletion	(indel)	mutations	in	one	or	several	of	the	genes.	To	get	these	combinations	in	a	minimal	number	of	operations,	we	co-transfected	Cas9	(GFP_2A_Cas9)	with	either	sgRNAs	against	B4Gal-T1	and	–T3	or	against	B4Gal-T1,	-T2	and	–T3	or	sgRNAs	against	B4Gal-T1	and	–T2	in	the	same	transfection	(Supporting	Information,	Table	S3).	After	transfection	and	single	cell	cloning,	we	carried	out	deep	sequencing	to	identify	the	genomic	changes	in	the	targeted	sequences.	We	aimed	to	identify	clones	with	exclusively	out-of	frame	indels	in	one	or	more	of	the	target	sequences	leading	 to	 a	 potentially	 functional	 knockout	 of	 the	 targeted	 glycosyltransferase(s)	 to	investigate	the	effect	on	N-glycan	galactosylation.	In	a	second	round	of	transfections,	we	aimed	to	generate	clones	with	indels	in	combinations	of	three	or	all	four	targeted	B4Gal-Ts.	Therefore	we	co-transfected	GFP_2A_Cas9	with	either	sgRNAs	against	B4Gal-T1	and	–T4	or	against	B4Gal-T1	into	a	clone	with	confirmed	indels	in	B4Gal-T2	and	–T3	(Table	1).	In	our	 study,	 a	 total	 of	 109	potential	deletion	 clones	were	deep	 sequenced	 for	 genomic	indels	in	the	targeted	regions	(Supporting	Information,	Table	S5).	Out	of	these,	23	clones	revealed	an	unclear	genotype	for	one	or	more	targets	(presence	of	in-frame	indel	or	indel-frequency	between	5-98%).	These	were	discarded.	We	expanded	clear	single-	and	multi-KO	clones	of	 1–4	 targets	 (indel	 frequencies	>98%).	Next,	we	 isolated	multiple	 independent	clones	for	each	genotype	to	study	true	biological	replicates	of	the	phenotypes,	in	total	17	clones	(Table	1).	One	clone	(WT	ctr)	which	showed	no	insertion	or	deletion	was	additionally	selected	to	serve	as	a	control	for	the	analysis	of	growth	and	N-glycan	profiles.	A	second	clone	(T2-3-KO	ctr)	which	did	not	reveal	additional	indels	after	the	second	round	of	transfection	was	also	characterized	to	investigate	the	impact	of	transfection	and	subcloning	on	growth	and	N-glycan	profile.	
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3.2.	Effect	on	growth	from	different	B4Gal-T-KO´s	and	indel	combinations		The	aim	of	our	study	is	to	provide	a	CHO	platform	to	produce	recombinant	proteins	with	agalactosylated	N-glycans.	Through	engineering	cells	towards	G0-glycans,	the	N-glycans	are	altered	not	only	on	the	recombinant	protein,	but	also	on	host	cell	proteins.	As	cell	growth	performance	 is	 a	 substantial	 factor	 for	 industrial	protein	production	platforms,	we	 first	evaluated	 whether	 decreased	 N-glycan	 galactosylation	 influence	 CHO	 cell	 growth.	 We	carried	out	shake	flask	batch	experiments	with	selected	KO	clones,	the	parental	CHO-S	WT	as	well	as	two	control	clones	(Table	1).	Sampling	for	VCDs	and	viabilities	was	performed	every	24	h	for	the	time	course	of	seven	days.	The	WT	ctr	clone	was	identified	to	have	similar	growth	 and	 viability	 to	 CHO-S	WT	 (Fig.	 1).	 Double-KO	 of	 B4Gal-T1	 and	 –T3	 (T1-3-KO)	indicated	slightly	decreased	growth	compared	to	CHO-S	WT	and	WT	ctr	(Fig.	1A).	The	two	clones	with	 frame-shifts	 in	 B4Gal-T3	 (T3-KO	A	&	T3-KO	B)	were	 not	 influenced	 in	 cell	growth	and	reached	slightly	higher	maximal	VCDs	than	CHO-S	WT	(Fig.	1A).	Furthermore,	the	 double-KO	 clone	 with	 indels	 in	 B4Gal-T2	 and	 -T3	 (T2-3-KO)	 revealed	 growth	comparable	 to	 CHO-S	WT	 and	WT	 ctr	 (Fig.	 1B).	 The	 T2-3-KO	 ctr	 clone	 exhibited	 lower	growth	compared	to	 the	growth	curve	of	 the	parental	T2-3-KO	clone	(Fig.	1B).	The	 four	triple-KO	clones	with	frame-shifts	in	B4Gal-T1,	-T2	and	-T3	(T1-2-3-KO)	and	the	three	T1-2-3-4-KO	mutants	had	decreased	growth	 compared	 to	CHO-S	WT	 (Fig.	 1B,	 Fig.	 1C).	The	three	T2-3-4-KO	 clones	had	heterogeneous	 growth	and	 compared	to	CHO-S	WT,	 similar	maximal	VCD	(T2-3-4-KO	C),	lower	maximal	VCD	(T2-3-4-KO	K)	or	increased	maximal	VCD	(T2-3-4-KO	 H)	 was	 observed	 (Fig.	 1D).	 Lastly,	 the	 three	 T1-2-KO	 clones	 exhibited	 also	heterogeneous	growth	but	clone	T1-2-KO	B	reached	similar	maximal	viable	cell	densities	compared	to	CHO-S	WT	(Fig.	1E).	Altogether,	the	engineered	clones	revealed	a	notable	variation	in	growth	within	groups	of	clones	with	indels	in	the	same	target	genes.	Whereas	T1-2-3-KO	and	T1-2-3-4-KO	clones	
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had	decreased	growth	compared	to	CHO-S	WT,	clones	with	other	indel	combinations	could	grow	to	similar	maximal	viable	cell	densities	as	CHO-S	WT.			
3.3.	Effects	of	B4Gal-T-KO´s	on	secretome	N-glycan	profiles	To	investigate	the	activities	of	the	targeted	β-1,4-galactosyltransferases	within	protein	N-glycosylation,	we	analyzed	 secretome	 samples	of	 CHO-S	WT,	 the	 control	 clones	 and	 the	different	KO-clones	with	indels	in	1-4	sequences	for	the	targeted	B4Gal-T-genes	(Table	1).	To	examine	the	contribution	of	the	targeted	B4Gal-Ts	within	galactosylation	of	the	different	N-glycan	branches,	we	studied	the	remaining	levels	of	N-glycan	galactosylation	in	clones	with	combinatorial	disruption	of	B4Gal-Ts.	To	probe	the	effect	of	the	generated	indels	on	the	secretome	N-glycans	of	the	selected	clones,	we	analyzed	supernatant	samples	harvested	five	days	after	seeding.	Secretome	samples	were	centrifuged	and	filtered	to	remove	cells	and	cell	debris	and	up-concentrated	before	total	N-glycans	were	labeled	and	analyzed	by	HPLC/MS.	As	presented	in	supplementary	Figure	1,	the	complex	bi-antennary	di-sialylated	N-glycan	structure	(A2FG2S2)	was	the	major	structure	within	 the	CHO-S	WT	secretome.	Notably,	in	the	CHO-S	WT	secretome,	only	one	minor	peak	(0.7%)	of	G0-N-glycan	could	be	annotated	(supplementary	Fig.	1).	T3-KO,	T2-3-KO,	and	T2-3-4-KO	clones	showed	a	similar	N-glycan	pattern	 to	WT	but	G0	structures	were	only	present	 in	T2-3-KO	and	T2-3-4-KO	clones	 (Fig.	 2).	 However,	 within	 the	 annotated	 N-glycan	 structures,	 the	 T1-3-KO	 clone	exhibited	a	total	of	~65%	G0	structures,	but	still	displayed	~10%	mono-galactosylated	N-glycans	 in	 the	 secretome	 (Fig.	 2).	 Compared	 to	 CHO-S	WT,	 indels	 in	 B4Gal-T1	 and	 –T2	resulted	in	the	absence	of	G4	 forms,	reduced	G3	and	G2	 forms	and	 increased	G1	and	G0	proportions	(Fig.	2)	leading	to	increased	overall	heterogeneity	in	N-glycan	galactosylation	(supplementary	Fig.	1).	T1-2-KO	clones	overall	showed	decreased	galactosylated	N-glycans	compared	 to	 WT	 (~61%	 galactosylated	 structures)	 and	 revealed	 ~24%	 galactosylated	structures.	
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In	 contrast,	 we	 could	 only	 annotate	 ~1%	 galactosylated	 N-glycan	 structures	 in	 the	secretomes	of	T1-2-3-KO	and	T1-2-3-4-KO	clones	(Fig.	2).	The	major	N-glycan	structures	of	T1-2-3-KO	and	T1-2-3-4-KO	clones	were	A2FG0,	A3FG0	and	A4FG0.	The	bi-galactosylated	structures,	which	were	the	predominant	N-glycans	in	CHO-S	WT	and	WT	ctr	clone,	were	not	present	anymore	(see	Fig.	2	and	supplementary	Fig.	1).	Furthermore,	the	additional	B4Gal-T4	indel	in	T1-2-3-4-KO	clones	did	not	increase	G0	proportions	or	eliminate	G1	N-glycans	when	compared	to	T1-2-3-KO	cell	lines	(Fig.	2).	Altogether,	disruption	of	B4Gal-T2	 in	conjunction	with	B4Gal-T1	and	–T3	decreased	 the	galactosylated	secretome	N-glycan	proportion	from	~10%	(T1-3-KO)	down	to	~1%	(T1-2-3-KOs)	and	the	secretome	N-glycans	of	the	triple-	and	quadruple-KOs	were	dominated	by	agalactosylated	bi-,	tri-	and	tetra-antennary	structures	with	A2FG0	as	the	dominating	N-glycan	structure	(supplementary	Fig.	1).	To	examine	the	role	of	the	four	targeted	B4Gal-Ts	within	protein	N-glycan	galactosylation,	we	 studied	 the	 levels	 of	 agalactosylation	 in	 the	 secretome	 samples	 in	 a	 comparative	approach	 (Fig.	 2).	 Confirming	 that	 B4Gal-T1	 is	 the	 most	 active	 N-glycan	 β-1,4-galactosyltransferase,	 we	 furthermore	 studied	 the	 presence	 of	 agalactosylation	without	(clone	T3-KO	A	and	T1-3-KO)	and	with	additional	KO	of	B4Gal-T2	(clones	T1-2-3-KO	and	T2-3-KO)	 to	 investigate	 its	 contributing	 role	 in	N-glycan	 galactosylation,	which	 has	 not	previously	been	studied	 in	exact	 terms.	Therefore,	we	compared	 two	sets	of	 two	clones,	differing	in	their	genotype	by	the	KO	of	B4Gal-T2.	In	the	first	comparison,	the	single	KO	of	B4Gal-T3	exhibited	no	G0-N-glycans,	where	the	double-KO	of	B4Gal-T2	and	–T3	revealed	~6%	G0-N-glycans	 (Fig.	 2).	 Similarly,	 comparing	 the	N-glycan	proportion	with	 terminal	GlcNAc	of	clone	T1-3-KO	and	T1-2-3-KO	clones,	the	additional	KO	of	B4Gal-T2	in	the	triple-KO	cell	lines	increased	the	G0-N-glycan	proportion	by	~10%.		
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3.4.	 Tailored	Rituximab	 and	 EPO	N-glycosylation	 after	 B4Gal-T-double	 and	 triple-
KO’s	To	prove	that	engineered	secretome	N-glycans	will	also	be	represented	on	rituximab	and	EPO	 which	 we	 used	 as	 model	 proteins,	 we	 transfected	 a	 rituximab-	 or	 EPO-encoding	plasmid	 into	CHO-S	WT	and	KO-clones	T3-KO	A,	T2-3-KO,	T1-3-KO	and	T1-2-3-KO.	Cells	were	 transfected	 and	 rituximab-	 or	 EPO-containing	 supernatants	 were	 harvested	 after	three	days.	After	purification,	we	analyzed	the	corresponding	N-glycan	structures	within	the	different	KO	cell	lines.		Clones	 T1-3-KO	 and	 T1-2-3-KO	 showed	 predominantly	 G0-N-glycans	 in	 the	 secretome	samples	and	were	expected	to	also	reveal	predominantly	G0	structures	on	the	transfected	rituximab.	 CHO-S	WT,	 clone	 T3-KO	 A	 and	 T2-3-KO	 displayed	 comparable	 rituximab	 N-glycan	profiles	with	G0	and	G1	as	prevalent	structures	with	both	~40%	of	total	rituximab	N-glycans	 (Fig.	 3A).	 In	 contrast,	 rituximab	purified	 from	clones	T1-2-3-KO	and	T1-3-KO	clones	was	mostly	N-glycosylated	by	bi-antennary	G0	 structures,	whereas	G2	structures	were	missing,	which	is	in	line	with	secretome	N-glycans	of	these	clones.	Notably,	double-KO	of	B4Gal-T1	and	–T3	in	T1-3-KO	resulted	in	higher	G0-N-glycan	proportions	on	rituximab	(~84%)	 than	 in	 clone	 T1-2-3-KO	 (~68%).	 Furthermore,	 triple-KO	 clone	 T1-2-3-KO	 had	increased	high-mannose	(HM)	structures	on	rituximab	when	compared	to	 the	other	cell	lines.	Figure	3B	presents	a	detailed	comparison	of	rituximab	N-glycans	purified	 from	T1-3-KO	and	T1-2-3-KO	A.	Here	the	bi-antennary,	non-galactosylated	A2FG0	was	clearly	the	main	structure.	However,	we	could	also	annotate	HM,	A2G0	and	A2FG1	N-glycans.	Thereof	A2FG1	was	found	in	both	clones	to	comparable	amounts	(~2-3%)	but	total	HM	proportions	were	higher	in	T1-2-3-KO	(15%)	than	in	T1-3-KO	(5.8%),	represented	by	Man5,	Man7,	Man8	and	Man9	 structures.	 Additionally,	 cell	 growth	 after	 rituximab	 transfection	was	 comparable	
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between	CHO-S	WT,	WT	ctr,	T3-KO	A	and	T1-3-KO	(supplementary	Fig.	2)	whereas	clones	T2-3-KO	and	T1-2-3-KO	revealed	increased	viable	cell	concentrations	on	day	three.	For	transiently	expressed	EPO,	the	N-glycan	profiles	of	CHO-S	WT,	T3-KO	A	and	T2-3-KO	are	 similar	 where	 annotated	 N-glycan	 structures	 predominantly	 harbor	 ≥4	 galactose	residues;	however	G0	forms	are	not	present	in	EPO	from	CHO-S	WT	(Fig.	3C).	In	contrast,	double-KO	of	B4Gal-T1	and	–T3	resulted	in	increased	G0	proportions	(~72%)	whereas	G3-	and	G4-glycans	could	not	be	identified	on	EPO	purified	from	T1-3-KO.	Analyzing	N-glycan	structures	 of	 EPO	 from	 the	 triple-KO	 clone	 T1-2-3-KO	 A,	 we	 could	 only	 annotate	agalactosylated	and	mono-galactosylated	N-glycans	(supplementary	Fig.	3).	Overall,	disruption	of	B4Gal-T1	and	–T3	with	or	without	additional	disruption	of	B4Gal-T2	resulted	in	rituximab,	which	only	harbored	~2-3%	galactosylated	N-glycans.	On	the	other	hand,	single	disruption	of	B4Gal-T3	or	disruption	of	both	B4Gal-T2	and	–T3,	did	not	change	rituximab	N-glycosylation	compared	to	CHO-S	WT	(Fig.	3A).	However,	disruption	of	B4Gal-T2	 in	 addition	 to	 indels	 in	 B4Gal-T1	 and	 –T3	 increased	 the	 G0	 N-glycan	 proportion	 of	transiently	expressed	EPO	from	~72%	to	~91%	(Fig.	3C).		
	
4.	Discussion		Since	 recombinant	 proteins	 with	 agalactosylated	 N-glycans	 can	 be	 of	 interest	 for	 the	therapy	 of	 several	 diseases,	we	 aimed	 to	 engineer	 CHO-S	 cells	 to	 reveal	predominantly	agalactosylated	N-glycans	on	secreted	proteins	and	on	transiently	expressed	rituximab	and	EPO.	In	a	previous	study	in	CHO-K1	derived	cell	lines,	disruption	of	B4Gal-T1,	-T2	and	–T3	resulted	in	prevalently	agalactosylated	N-glycans	on	rituximab	and	EPO	whereas	the	effects	of	B4Gal-T	disruptions	on	cell	growth	and	the	glycosylation	of	total	secreted	proteins	were	not	addressed[34].	Within	this	work,	we	also	aimed	to	assess	the	impact	of	B4Gal-T	indels	on	cell	growth	and	analyze	N-glycans	and	cell	growth	 in	groups	of	clones	with	 the	same	combination	 of	 indels	with	 respect	 to	 clonal	 variation.	We	 investigated	 if	 disruption	 of	
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B4Gal-T1,	-T2	and	–T3	in	CHO-S	cells	is	sufficient	to	produce	predominantly	agalactosylated	proteins	and	if	additional	disruption	of	B4Gal–T4	is	of	any	benefit	with	regards	to	N-glycan	agalactosylation	and	decreased	N-glycan	heterogeneity.	Additionally,	we	analyzed	possible	B4Gal-T	branch	preferences	 after	 combinatorial	KO	of	B4Gal-T-isoforms.	We	performed	CRISPR/Cas9-mediated	multiplexing	for	all	four	targets	followed	by	single	cell	cloning	and	genotype	 characterization	 via	 deep	 sequencing.	 Clones	 with	 different	 combinations	 of	B4Gal-T-indels	 were	 expanded	 and	 further	 characterized	 with	 regards	 to	 cell	 culture	performance,	 N-glycosylation	 of	 total	 secreted	 host	 cell	 proteins	 and	N-glycosylation	 of	transiently	expressed	rituximab	and	EPO.		Targeting	multiple	genes	in	one	transfection	with	CRISPR/Cas9	is	a	time	saving	method	to	generate	clones	with	different	indel-combinations	in	several	genes.	However,	clones	often	have	in-frame	indels	which	may	not	disrupt	the	gene(s)[37].	Since	increasing	the	number	of	co-transfected	sgRNAs	might	increase	the	proportion	of	functional	in-frame	indels	(and	thereby	 render	 disrupting	 mutations	 in	 other	 genes	 unusable),	 we	 employed	 two	multiplexed	transfection	rounds.	First,	we	co-transfected	with	sgRNAs	against	B4Gal-T1,	-T2	and	–T3	or	sgRNAs	against	B4Gal-T1	and	–T3	or	sgRNAs	against	B4Gal-T1	and	–T2.	In	a	second	 round	 of	 transfection,	 we	 built	 up	 triple-KO	 (T1-2-3-KO	 and	 T2-3-4-KO)	 and	quadruple	KO	clones	(T1-2-3-4-KO)	based	on	transfections	of	 the	T2-3-KO	cell	 line	with	sgRNAs	against	B4Gal-T3	and	–T4.	Although	 it	 is	 faster,	a	 limitation	of	 this	multiplexing	method	is	that	not	all	desired	KO	combinations	might	appear	after	deep	sequencing	of	single	cell	clones.	Ideally,	the	selection	of	clones	would	include	at	least	three	clones	with	the	same	gene	disruptions	to	ensure	that	the	resulting	phenotype	is	not	due	to	clonal	variation	upon	subcloning.	 The	 efficiency	 of	 indel-generation	 and	 clone	 survival	 are	 therefore	 critical	attributes	when	performing	multiplexed	experiments	with	CRISPR/Cas9.			
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Besides	influencing	N-glycosylation,	disrupting	the	four	targets	also	influenced	cell	culture	performance	where	clones	with	indels	in	B4Gal-T1,	-T2	and	–T3	revealed	decreased	growth	when	compared	to	CHO-S	WT	(Fig.	1).	The	reduced	growth	in	clones	with	T1-2-3-KO	and	T1-2-3-4-KO	could	be	associated	to	the	high	G0-N-glycan	proportions	of	their	secretome	(Fig.	2)	or	be	linked	to	clonal	variation	which	is	known	to	be	challenging	when	working	with	CHO	cells[38].	However,	glycosylation	plays	a	main	role	in	cell-cell	communication	via	e.g.	endocytosis,	 receptor	 activation,	 and	 cell	 adhesion[39]	 and	 glycosylation	 engineering	therefore	might	impact	cultivation	performance.	We	also	report	heterogeneous	cell	growth	of	clones	within	the	generated	indel	combination	groups.	This	can	also	be	a	result	of	clonal	variation	 after	 subcloning	 or	 due	 to	 off-target	 effects	 after	 sgRNA	 and	 GFP_2A_Cas9	 co-transfections.	However,	we	used	the	sgRNA	design	guidelines	and	identical	Cas9-version	published	in	an	earlier	study	which	did	not	show	significant	off-target	events[13].	While	subcloning	did	not	 influence	 growth	of	 the	WT	ctr	 clone,	 subcloning	of	T2-3-KO	 lead	 to	decreased	 growth	 of	 the	 T2-3-KO	 ctr	 (Fig.	 1).	 Nonetheless,	 our	 results	 indicate	 that	subcloning	 had	no	 impact	 on	 secretome	N-glycosylation	 as	 the	WT	 ctr	 and	 T2-3-KO	 ctr	clones	 showed	 comparable	 N-glycan	 structures	 to	 their	 parental	 cell	 lines	 in	 the	 batch	cultivation	(Fig.	2).		In	contrast	 to	a	previous	study,	which	suggested	B4Gal-T1-4	to	all	be	active	 in	N-glycan	galactosylation[31],	 our	 results	 indicate	 that	B4Gal-T1,	 -T2	 and	–T3	are	 the	most	active	B4Gal-Ts	in	the	N-glycosylation	pathway	of	CHO-S	cells	and	that	B4Gal-T4	has	very	little	or	no	contribution	to	galactosylation	of	N-glycans	in	CHO-S	cells.	The	lack	of	N-glycosylation	activity	of	B4Gal-T4	in	our	work	supports	another	study	where	B4Gal-T4	was	reported	to	be	 active	 in	 the	 galactosylation	 of	 mucin-type	 core	 2	 branching	 in	 the	 O-glycosylation	pathway[32].		
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Furthermore,	B4Gal-T5,	-T6	and	–T7	(and	potentially	unknown	B4Gal-Transferases)	in	sum	contribute	only	up	to	~3%	N-glycan	galactosylation	of	the	secretome	as	seen	in	Figure	2.	The	single	galactose	found	on	G1	tetra-antennary	N-glycans	indicates	that	the	remaining	source	 for	 N-glycan	 galactosylation	 in	 the	 quadruple-KOs	 can	 only	 transfer	 a	 single	galactose	on	the	N-glycan	structure.	However,	peaks	very	close	to	the	baseline	could	not	be	annotated	 and	might	 harbor	 little	 amounts	 of	 structures	with	more	 than	 one	 galactose.	Whether	the	galactosylation	activity	in	the	quadruple	KO	clones	is	carried	out	by	B4Gal-T5,	-T6,	–T7	or	a	combination	thereof	has	to	be	investigated	further.		We	conclude	that	B4Gal-T1	is	the	main	active	N-glycan	B4Gal-T	in	clone	T2-3-KO.	Since	the	T2-3-KO	clone	still	showed	up	G1,	G2,	G3	and	G4	structures	and	all	KO	cell	lines	with	indels	in	B4Gal-T1	lack	G4	N-glycans,	B4Gal-T1	is	very	likely	capable	of	transferring	galactose	to	all	 four	 branches.	 Therefore	 we	 suggest	 that	 B4Gal-T1	 is	 the	 most	 active	 N-glycan	processing	B4Gal-T	within	 the	 family	of	 β-1,4-galactosyltransferases	of	CHO-S	 cells.	 The	predominant	activity	of	B4Gal-T1	in	N-glycan	galactosylation	within	our	study	is	in	line	with	previous	work	in	other	CHO	cell	 lines[34].	Moreover,	we	conclude	that	B4Gal-T2	activity	contributes	to	~5-10%	of	N-glycan	galactosylation	since	B4Gal-T2-KO	in	addition	to	KO	of	B4Gal-T3	or	B4Gal-T1	and	-T3	increased	G0	structures	up	to	10%	(Fig.	2).		The	remaining	level	of	rituximab	galactosylation	of	the	CHO-S	derived	clone	T1-3-KO	(~2-3%)	 is	 comparable,	 yet	 slightly	 higher	 to	 another	 study	 where	 decreased	 rituximab	galactosylation	(~1%)	was	achieved	by	knocking	out	B4Gal-T1	and	–T3	in	CHO-K1	derived	cell	 lines[34].	 This	 difference	 in	 remaining	 N-glycan	 galactosylation	 could	 be	 due	 to	differences	in	the	N-glycan	pathways	of	the	cell	lines	used	(CHO-S	versus	CHO-K1)[34]	or	due	to		clonal	variation.	Although	B4gal-T3-KO	lead	to	decreased	N-glycan	galactosylation	activity	 when	 combined	 with	 B4Gal-T2-KO,	 single	 B4Gal-T3-KO	 did	 not	 decrease	galactosylation	at	all	(Fig.	2).	This	suggests	that	B4Gal-T3	has	only	a	minor	role	in	CHO-S	N-
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glycosylation	or	 that	 its	disrupted	N-glycan	 transferase	 function	can	be	compensated	by	B4Gal-T1	and	–T2	activity	in	the	T3-KO	clone.			For	glycoproteins	harboring	tri-	or	tetra-antennary	N-glycans,	as	is	the	case	for	EPO,	KO	of	B4Gal-T1	and	–T3	is	not	sufficient	to	produce	mainly	agalactosylated	glycoproteins	(Fig.	3B	with	~20%	EPO	galactosylation	in	T1-3-KO),	whereas	rituximab	expressed	in	clone	T1-3-KO	resulted	in	only	~3%	galactosylated	structures	(Fig.	3A).	Therefore,	we	propose	that	bi-antennary	 N-glycosylated	 proteins	 as	 rituximab	 can	 be	 produced	 with	 mostly	agalactosylated	N-glycans	after	double-KO	of	B4Gal-T1	and	–T3	but	tri-	and	tetra-antennary	N-glycosylated	 secretome	 proteins	 as	 EPO	 additionally	 need	 KO	 of	 B4Gal-T2	 to	 be	predominantly	agalactosylated.	For	transiently	expressed	EPO	in	CHO-K1	derived	cells	with	triple-KO	of	B4Gal-T1,	-T2	and	–T3	the	proportions	of	galactosylated	N-glycans	were	found	to	be	~4%	in	an	earlier	study	[34].	 In	our	study	we	annotated	~6%	galactosylated	N-glycans	on	 transiently	expressed	EPO	 from	 the	 CHO-S	 derived	 triple-KO	 T1-2-3-KO	 A	 (Fig.	 3C).	 Although	 these	 results	indicate	 similar	 effects	 on	 galactosylation	 of	 EPO	 after	 disruption	 of	 two	 identical	 gene	targets,	deviations	could	be	related	to	differences	between	CHO-K1	and	CHO-S	expression	levels	of	non-targeted	B4Gal-T	isoforms.	We	conclude	that	engineering	cells	with	non-galactosylated	N-glycans	on	a	secretome	level	in	CHO-S	WT	 is	a	promising	strategy	 towards	producing	G0-IgG1	and	G0-EPO	on	a	later	stage.	Despite	the	divergent	gene	expression	levels	between	different	CHO	cell	lines[40]	this	engineering	strategy	 is	suitable	not	only	 for	CHO-K1[34]	but	also	 for	CHO-S	derived	cell	lines	as	utilized	in	our	work.	In	the	presented	study	the	triple-KO	with	~1%	galactosylated	structures	 on	 the	 secretome	 also	 showed	 predominantly	 agalactosylated	 N-glycans	 on	transiently	expressed	rituximab	with	only	~3%	galactosylated	N-glycans	and	on	transiently	expressed	EPO	with	remaining	~6%	galactosylated	N-glycan	structures.		
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	Within	 our	 triple-KO	 cell	 line	 T1-2-3-KO	 A,	 we	 also	 noticed	 a	 significant	 amount	 of	hypermannosylated	(HM)	structures	on	transiently	expressed	rituximab	(Fig.	3A	and	3B).	HM	 structures	 are	 a	 critical	 quality	 attribute	 within	 biopharmaceutical	 protein	production[41]	and	can	accumulate	during	cell	culture	performance.	Process	design	and	genetic	 engineering	 could	 be	 two	 possibilities	 to	 overcome	 accumulated	HM	 structures	which	might	represent	proteins	accumulated	in	the	Golgi-situated	N-glycan	machinery	after	disrupting	 Golgi-residing	 B4Gal-T1,	 -T2	 and	 –T3.	This	 disruption	might	 cause	 increased	traffic	and	residence	time	of	secretome	proteins	in	the	Golgi	lumen	without	being	further	processed	 by	 glycosyltransferases.	 Recent	 studies	 displayed	 increased	 processing	 of	 N-glycans	 after	 overexpression	 of	 Mgat4	 and	Mgat5	 which	 could	 result	 in	 decreased	 HM	structures[42].	In	 N-glycan	 analysis	 of	 secretome,	 rituximab	 and	 EPO	 from	 T1-2-3-KO	 clones	 we	 still	detected	remaining	galactosylated	structures.	Here,	adding	KO	of	B4Gal-T5,	-T6	or	–T7	on	clone	T1-2-3-KO	could	help	to	investigate	their	activities	within	the	galactoslyation	of	N-glycosylated	proteins	to	e.g.	remove	the	remaining	~3%	of	galactosylated	N-glycans	after	transient	rituximab	expression.		The	outcome	of	this	study	with	the	generation	of	different	amounts	of	G0,	G1,	G2,	G3	and	G4	forms	after	disruption	of	the	targeted	transferases	could	be	a	starting	point	to	construct	a	N-glycan	galactosylation	model	 for	 the	discussion	of	possible	branch	 specificities	within	B4Gal-T1,	 -T2,	 -T3	 and	 –T4	 as	 conducted	 in	 an	 earlier	 study[31].	 We	 suggest	 that	 the	function	of	B4Gal-T1	includes	galactosylation	of	all	four	N-glycan	branches	(Fig.	2),	although	its	branch	preference	needs	to	be	explored	further.	In	clone	T1-3-KO,	B4Gal-T2	is	suggested	to	be	the	most	active	B4Gal-T	and	only	mono-galactosylated	N-glycans	were	found	within	
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galactosylated	 structures	 (Fig.	 2).	 This	 indicates	 that	 B4Gal-T2	 N-glycosylation	 activity	includes	only	the	galactosylation	of	a	single	N-glycan	branch.	Studying	 the	 galactosylation	 levels	 of	T1-2-KO	 clones	 in	a	 similar	 approach	 leads	 to	 the	assumption	 that	B4Gal-T3	 is	at	 least	 capable	of	 transferring	 galactose	 to	up	 to	 three	N-glycan	branches	(Fig.	2).	As	presented	in	supplementary	Figure	1,	clones	with	T1-2-KO	were	identified	to	not	produce	N-glycans	with	decreased	heterogeneity	as	found	in	the	other	sets	of	KO	 combinations.	The	origin	of	 this	heterogeneity	 is	 the	 increased	presence	of	G1	N-glycan	forms.	However,	G1	forms	with	further	modifications	can	be	of	particular	interest	since	 they	 are	 the	platform	 for	 glycoPEGylation,	 a	method	 to	 attach	polyethylene	 glycol	(PEG)	on	biopharmaceuticals	to	increase	serum	half-life[43].			In	summary,	our	study	presents	the	necessity	of	disrupting	the	three	genes,	B4Gal-T1,	-T2	and	 –T3,	 to	 produce	 not	 only	 predominantly	 G0	 secretome	 proteins	 but	 also	 mainly	agalactosylated	rituximab	and	EPO	in	CHO-S	cells.	Further,	we	elucidated	different	N-glycan	galactosylation	 activities	 within	 the	 four	 targeted	 genes	 where	 B4Gal-T1	 is	 the	 most	contributing	enzyme	to	N-glycan	galactosylation	and	involved	in	the	galactosylation	of	all	four	N-glycan	branches.	Our	study	concludes	that	targeting	the	presented	targets	does	only	interfere	 with	 cell	 growth	 if	 B4Gal-T1,	 -T2,	 and	 –T3	 are	 disrupted	 simultaneously	 and	reveals	 the	 possibility	 to	 engineer	 tri-	 and	 tetra-antennary	 G0	 N-glycans,	 which	 are	naturally	not	produced	in	CHO-S	WT	cells	(supplementary	Fig.	1).	We	also	investigated	the	B4Gal-T2	activity	in	CHO-S	cells	and	conclude	that	its	galactosylation	activity	is	prevalent	to	one	N-glycan	branch	while	B4Gal-T4	has	no	N-glycan	galactosylation	activity	and	B4Gal-T3	 can	 galactosylate	 up	 to	 three	 N-glycan	 branches.	 Prior	 engineering	 of	 secretome	 N-glycans	in	a	WT	cell	gives	rise	to	the	flexibility	of	expressing	several	different	model	proteins	in	 the	 engineered	 cell	 line	 at	 a	 later	 stage.	 Such	 model	 proteins	might	 include	 already	marketed	antibodies	or	other	therapeutic	proteins.	With	our	cell	platform	that	prevalently	
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glycosylates	proteins	with	G0-N-glycans	we	demonstrate	 an	 alternative	 to	 galactosidase	treatment	 of	 recombinant	 proteins	 to	 investigate	 further	 beneficial	 in	 vitro	 and	 in	 vivo	characteristics	based	on	tailored	G0	N-glycosylation	profiles.		
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Table	1.	Overview	of	sgRNA/Cas9	transfections	and	generated	cell	lines.	The	first	round	of	transfections	was	performed	with	a	CHO-S	WT.	The	T2-3-KO	clone	was	used	as	parental	cell	line	for	the	second	transfection	round.	Values	in	brackets	are	generated	indels	in	bp	for	each	target	confirmed	by	deep	sequencing.	
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Figure	1.	 Growth	profiles	 of	 expanded	 clones	 in	batch	 cultivation.	 30	mL	volume	batch	cultivation	 with	 VCDs	 for	 the	 duration	 of	 seven	 days	 after	 sampling	 every	 24	 h	 (n=2).	Seeding	was	performed	at	3.0	x	105	cells/mL	and	error	bars	indicate	range	of	shake	flask	duplicates.	(A)	T3-KO	&	T1-3-KO,	(B)	T1-2-3-KOs,	(C)	T1-2-3-4-KOs,	(D)	T2-3-KOs,	(E)	T1-2-KOs.	
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Figure	2.	Secretome	N-glycan	profile	of	generated	B4Gal-T-KO-clones.	N-glycan	secretome	analysis	from	batch	cultivation	of	parental	cell	lines	and	KO	cell	lines	harvested	after	five	days	of	cultivation	and	normalized	to	area	under	the	curve	(AUC)	of	total	agalactosylated	(G0),	 mono-galactosylated	 (G1),	 bi-galactosylated	 (G2),	 tri-galactosylated	 (G3),	 tetra-galactosylated	(G4)	and	high-mannose	(HM)	N-glycan	peaks	per	cell	 line.	Increase	of	G0-proportion	is	given	in	%	after	additional	B4Gal-T2-KO	in	T2-3-KO	and	T1-2-3-KO	compared	to	T3-KO	B	and	T1-3-KO,	respectively.	Where	present,	error	bars	indicate	SD	of	three	(T1-2-3-KO,	T2-3-4-KO	and	T1-2-KO)	or	four	replicates	(T1-2-3-KO).		 	
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Figure	3.	Rituximab	and	EPO	N-glycosylation	profiles	in	WT	and	B4Gal-T	KO	cell	lines	after	transient	 transfection.	 (A)	 Comparison	 of	 rituximab	 N-glycans	 purified	 out	 of	 pooled	supernatants	within	shake	flask	duplicates	from	CHO-S	WT,	T3-KO	A,	T2-3-KO,	T1-2-3-KO	A	 and	 T1-3-KO	with	N-glycan	 proportions	 of	 agalactosylated	 (G0),	mono-galactosylated	(G1),	bi-galactosylated	(G2)	and	high-mannose	structures	(HM)	normalized	to	AUC	of	total	N-glycan	peaks	per	clone.	(B)	Detailed	N-glycan	profiles	of	rituximab	purified	out	of	pooled	supernatants	within	shake	flask	duplicates	from	T1-2-3-KO	A	(orange	line)	and	T1-3-KO	(black	 line)	 after	HPLC	 histogram	 annotation	 via	MS.	 (C)	 Comparison	 of	 EPO	N-glycans	purified	out	of	pooled	supernatants	within	shake	flask	duplicates	from	CHO-S	WT,	T3-KO	A,	T2-3-KO,	 T1-2-3-KO	 A	 and	 T1-3-KO	with	 N-glycan	 proportions	 of	 agalactosylated	 (G0),	mono-	(G1),	bi-	(G2),	tri-	(G3)	and	greater	or	equal	tetra-galactosylated	structures	(≥G4)	normalized	to	AUC	of	total	N-glycan	peaks	per	clone.	(D)	Detailed	N-glycan	profile	of	EPO	purified	 out	 of	 pooled	 supernatants	 within	 shake	 flask	 duplicates	 from		T1-2-3-KO	A.	
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